India is preparing new rules that could lead to immediate suspension of pharmaceutical licences if drug samples fail quality tests.
The health ministry is planning to introduce a notification that mandates the suspension of product licences for pharmaceutical companies found producing drugs that fail to meet quality standards. The move comes amid concerns over patient safety and increasing reports of drugs being declared “Not of Standard Quality” (NSQ) by government laboratories.
According to The Economic Times, the Central Drugs Standard Control Organisation (CDSCO), along with the Drugs Technical Advisory Board (DTAB), is leading the discussions. In a recent board meeting, the DTAB noted that once a drug is classified as NSQ, the company’s product licence must be suspended immediately. The licence would be reinstated only after the company provides a root cause analysis and implements a corrective and preventive action plan (CAPA). The board has also recommended changes in the Drug Rules to formalize this process.
The ministry is currently in discussions with state authorities and pharma industry bodies before issuing the notification. While the regulatory move is aimed at maintaining quality, it has triggered concern among pharma lobby groups, including the Federation of Pharma Entrepreneurs (FOPE). In its representation, FOPE acknowledged the importance of quality assurance but argued that many NSQ cases are technical in nature and not due to negligence or wrongdoing. The group has cautioned against hasty suspensions without proper investigation.
Industry groups have also raised questions about the accuracy and consistency of government laboratory testing. In some instances, samples that initially failed tests were later passed when re-evaluated by the Central Drugs Laboratory (CDL) in Kolkata. Stakeholders have requested that the investigation process include detailed reviews of testing procedures, lab compliance, and documentation from both manufacturers and regulators.
Further concerns were raised around the impact on manufacturers who have made large investments in facilities, research, and workforce development. Lobby groups argued that automatic suspension of product permissions could damage businesses without addressing systemic issues. Instead, they suggested strengthening the drug recall mechanism and conducting a proper impact assessment before implementing new penalties.
As India moves to tighten its drug quality regulations, the outcome of these discussions may shape the future relationship between pharma companies and regulators, balancing public safety with industry stability.
